Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharma Publishes Phase 2 Study Data in Major Peer-reviewed Journal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"ISA Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration With Regeneron","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharmaceuticals Receives US Orphan-Drug Designation for ISA101b in HPV16-Positive Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"UPMC Hillman Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals\u2019 Lead Immunotherapy ISA101b with Keytruda\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharmaceuticals Commences Patient Treatment in Third Phase 2 Clinical Trial with the Combination of ISA101b and Libtayo\u00ae (cemiplimab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long Term Study Confirms Efficacy of Isa Pharmaceuticals' T-cell Activating Immunotherapy in Combination With Checkpoint Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharmaceuticals Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 Induced Oropharyngeal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharmaceuticals Reports Highlights of Randomized Phase 2 Cancer Vaccine Trial in Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for ISA101b

    Menu

    ISA101b

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ISA Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ISA Pharmaceuticals Reports Highlights of Randomized Phase 2 Cancer Vaccine Trial in Head & Neck Cancer

              Details:

              ISA101b (cemiplimab) is a PD-1 inhibitor vaccine drug candidate, which is currently being evaluated for the treatment of patients with advanced HPV16-positive oropharyngeal cancer.

              Lead Product(s): ISA101b,Cemiplimab

              Therapeutic Area: Oncology Product Name: ISA101b

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ISA Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ISA Pharmaceuticals Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 Induced Oropharyngeal Cancer

              Details:

              ISA101b immunotherapy targets human papillomavirus type 16 (HPV16) positive cancers. It induces strong and specific immune responses to the HPV16 virus, and (re-)establishes a powerful and targeted T-cell immune response against infected and/or cancerous cells and tissues.

              Lead Product(s): ISA101b,Cemiplimab

              Therapeutic Area: Oncology Product Name: ISA101b

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 30, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ISA Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Long Term Study Confirms Efficacy of Isa Pharmaceuticals' T-cell Activating Immunotherapy in Combination With Checkpoint Inhibitor

              Details:

              ISA101b, consists of 12 synthetic long peptide derived from oncogenic protein of HPV 16 virus in combination with nivolumab in cancer demonstrated deep and durable responses have a positive effect on patient prognosis with patients disease-free for more than 44 months.

              Lead Product(s): ISA101b,Nivolumab

              Therapeutic Area: Oncology Product Name: ISA101b

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ISA Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b

              Details:

              In a new phase 2 study, ISA101b induces strong and specific immune responses to HPV16 virus proteins, and (re-)establishes a powerful T-cell immune response against virus infected and/or cancerous cells and tissues.

              Lead Product(s): ISA101b,Cemiplimab

              Therapeutic Area: Oncology Product Name: ISA101b

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 14, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ISA Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ISA Pharmaceuticals Commences Patient Treatment in Third Phase 2 Clinical Trial with the Combination of ISA101b and Libtayo® (cemiplimab)

              Details:

              Libtayo is an anti-PD-1 antibody that is being jointly developed by Regeneron and Sanofi. The phase 2 study enrols patients with advanced HPV16 positive oropharyngeal head and neck cancer that failed previous anti-PD1 treatment.

              Lead Product(s): ISA101b,Cemiplimab

              Therapeutic Area: Oncology Product Name: ISA101b

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ISA Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals’ Lead Immunotherapy ISA101b with Keytruda®

              Details:

              The study in previously untreated patients with intermediate-risk head and neck cancer associated with human papilloma virus subtype 16 (HPV-16) will evaluate the efficacy of ISA101b and pembrolizumab (Keytruda®) in combination with cisplatin and radiotherapy.

              Lead Product(s): ISA101b,Pembrolizumab

              Therapeutic Area: Oncology Product Name: ISA101b

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: UPMC Hillman Cancer Center

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ISA Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ISA Pharmaceuticals Receives US Orphan-Drug Designation for ISA101b in HPV16-Positive Cervical Cancer

              Details:

              ISA101b is a clinical-stage immunotherapy targeting HPV16-induced diseases such as cervical and oropharyngeal cancer. It induces specific immune responses to the oncogenic E6 and E7 proteins of HPV16 and is based on ISA's proprietary Synthetic Long Peptide (SLP®) technology.

              Lead Product(s): ISA101b,Cemiplimab

              Therapeutic Area: Oncology Product Name: ISA101b

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Regeneron Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration With Regeneron

              Details:

              The new oropharyngeal cancer trial is the 3rd trial planned under the clinical collaboration between ISA Pharmaceuticals and Regeneron. ISA101b is currently in a Phase 2 trial for first- and second-line HPV16+ head-and-neck cancer in combination with Libtayo.

              Lead Product(s): ISA101b,Cemiplimab

              Therapeutic Area: Oncology Product Name: ISA101b

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: ISA Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 17, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ISA Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ISA Pharma Publishes Phase 2 Study Data in Major Peer-reviewed Journal

              Details:

              A strong correlation was seen between strength of the HPV-specific immune response and overall survival (OS).

              Lead Product(s): ISA101b

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 19, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY